OTLK Profile
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, specializes in the development and commercialization of monoclonal antibodies targeting various ophthalmic conditions. Headquartered in Iselin, New Jersey, the company focuses on advancing innovative therapies for eye diseases through rigorous clinical research and strategic partnerships.
The company's flagship product candidate is ONS-5010, an ophthalmic formulation of bevacizumab designed to address retinal diseases, including wet age-related macular degeneration (AMD). ONS-5010 is currently undergoing Phase III clinical trials, aimed at demonstrating its efficacy and safety for treating wet AMD and other retinal conditions. This product is expected to offer a significant advancement over current treatment options, potentially improving visual outcomes and quality of life for patients.
Outlook Therapeutics has established several key collaborations to enhance its research and development capabilities and expand its market reach. The company holds collaboration and license agreements with IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. These partnerships are instrumental in supporting the development, manufacturing, and commercialization of its ophthalmic therapies on a global scale.
Originally known as Oncobiologics, Inc., the company rebranded to Outlook Therapeutics, Inc. in November 2018 to better reflect its focus on ophthalmic therapies. Founded in 2010, Outlook Therapeutics is committed to advancing cutting-edge treatments for serious eye diseases, leveraging its clinical-stage pipeline and strategic alliances to drive innovation and improve patient outcomes in the field of ophthalmology.
|
